Related Experiment Video
Updated: May 13, 2026
04:47
Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
Spironolactone improves endothelial dysfunction in ankylosing spondylitis.
Ashit Syngle1, Kanchan Vohra, Dinesh Khichi
1Healing Touch City Clinic, Chandigarh, India.
Clinical Rheumatology
|March 19, 2013
Summary
Spironolactone treatment significantly improved endothelial dysfunction and reduced inflammation in ankylosing spondylitis (AS) patients. This study highlights spironolactone
Area of Science:
- Rheumatology
- Cardiovascular Medicine
- Pharmacology
Background:
- Chronic inflammation in ankylosing spondylitis (AS) is linked to endothelial dysfunction and accelerated atherosclerosis.
- This contributes to premature cardiovascular disease and mortality in AS patients.
- Spironolactone has shown potential in reducing inflammation and improving endothelial function in other inflammatory conditions like rheumatoid arthritis.
Purpose of the Study:
- To investigate the therapeutic effects of spironolactone on endothelial dysfunction and inflammatory disease activity in anti-tumor necrosis factor (TNF)-naive AS patients.
Main Methods:
- A 12-week open-label study involving 20 anti-TNF-naive AS patients with high disease activity.
- Measurements included inflammatory markers (BASDAI, BASFI, ESR, CRP), serum nitrite, and brachial artery flow-mediated dilation (FMD).
- Patients received oral spironolactone (2 mg/kg/day); a healthy control group was included for comparison.
Main Results:
- AS patients exhibited significantly impaired FMD at baseline compared to controls.
- Spironolactone treatment led to significant improvements in FMD, reduced nitrite levels, and decreased inflammatory markers (BASDAI, BASFI, ESR, CRP).
- All measured parameters showed statistically significant improvements post-treatment.
Conclusions:
- Endothelial dysfunction is an integral component of the ankylosing spondylitis disease process.
- Spironolactone demonstrates efficacy in simultaneously improving endothelial function and reducing inflammatory disease activity in AS patients.
- This is the first study to establish spironolactone's dual benefit in this patient population.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...